Company intelligence / Profile preview

Nanotis

Ownership: Private
Development stage: Preclinical

Overview

Nanotis has developed a saliva-based digital inspection/testing platform for rapid, highly sensitive detection of infectious diseases such as influenza and COVID‑19. The company’s technology aims to enable accurate point-of-care diagnostics without the need for specialized technical skills. Early results indicate high sensitivity and potential for broad application, but no published clinical trial data or regulatory approvals are noted as of June 2025.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDigital diagnostic platformBiosensor-based technology
Industry: Protein Biomarker Diagnostics

Partnerships

Taisho Pharmaceutical (strategic investor/funding partner)Research collaboration with Department of Emergency and Disaster Medicine at Institute of Science Tokyo

Beyond the preview

Go deeper on Nanotis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanotis.

Explore the full profile